LEX Diagnostics

1 known investors

LEX Diagnostics (now QuidelOrtho) develops the NULEXA System, a CLIA-waived molecular PCR diagnostic platform that delivers point-of-care test results in under 10 minutes for respiratory infections and other conditions. The system is designed for healthcare facilities including physician offices, pharmacies, and urgent care centers.